Data & Analytics
"Social can enable a better starting point to yield better questions and thus make surveys less in number yet greater in value."
The move away from a fee-for-service reimbursement model and the arrival of promising new technology have created demand for big data in healthcare.
2015 marks the second straight double digit increase in spend, which was driven by recent launches and specialty brands.
Analyst survey says docs want outcomes benefit from PCSK9s; Allergan licenses early-stage Alzheimer's drugs; Pfizer and IBM partner in Parkinson's disease
The results of a failed trial for Lilly's CEPT inhibitor has analysts saying there is little hope for Merck's drug in the same class.
Given the value of its data and its relatively backward security measures, the healthcare industry has become a prime target for hackers. But industry experts say changes are afoot.
Time is everything, yet no one has enough of it. But especially in healthcare marketing, time and timing win customers.
Consumers are more likely to use health information websites they find easier to navigate than those perceived as trustworthy, like government sites, new research shows.
Analysis questions Addyi's effectiveness; Horizon is subpoenaed about its patient assistance programs; AstraZeneca sells non-U.S. rights to constipation drug
With these changes coming to healthcare from precision medicine, it may no longer be acceptable to do generic or broad marketing campaigns in hopes of catching the small group of people who may benefit from a device or treatment.
The agency announced a partnership with Vencore Health Analytics to help pair rare disease patients with drugmakers.
Despite conventional wisdom that the 23andMe business breakthrough is the direct-to-consumer model, it's also the consolidation of genetic testing, diagnosis and drug development that has the potential to change the industry.
Healthcare spending rose in 2014; Publicis reorganizes its agency network; proposed New Jersey bill would punish drugmakers that move abroad
Healthcare may seem to have been unscarred by the ongoing rash of high-profile cyber-attacks, at least compared with retail and financial organizations. But to hear security pros tell it, the industry is increasingly finding itself as much of a target as companies in other sectors—if not more of one. Karen Epper Hoffman surveys the potential damage
Specialty medicines will keep drug spend trending upward through the next five years.
If more physicians begin participating in late-phase research efforts—and work to educate patients about these opportunities—we can expect new innovations in treatment solutions to come more quickly to market.
Soon, IBM says, Watson will be used by one particular pharma company to create a website where, once a drug is prescribed, patients can ask questions in their own words and the website will provide answers in near real-time.
A pair of surveys paint a complicated picture of what direction pharma access to healthcare providers is going.
The public said drugmakers spend too much money on marketing to doctors and patients
Initiatives in Europe follow the US example when it comes to requiring manufacturers to report information about financial relationships with physicians.
Amgen reportedly asks Repatha patients seeking financial assistance for personal health information; Valeant faces more scrutiny of business model; the FDA approves new J&J cancer drug
By equipping patients with biosensors, wearable devices and mobile apps, clinical R&D teams have the opportunity to gain unprecedented insight about the patient experience.
The firm is the primary vendor for the drugmaker's global commercial analytics.
An analysis of R&D data from 14 large drugmakers found that pharma is having renewed success in bringing medicines to market.
Report finds Americans overpay for cancer drugs; Clinton proposes end to pharma DTC as a tax write-off; Gilead HCV combo is effective across all strains of the virus
Accenture found that life-sciences executives believe that smart tools and devices will be the catalyst for drugmakers to move forward with beyond-the-pill initiatives.
As the value proposition of real-world data to drugmakers becomes increasingly attractive, services companies are partnering to capitalize on the opportunity.
Cardiologists say that up to 15% of their patients could be on PCSK9 inhibitors next year; FDA committee to evaluate new Oxycodone version
Sales reps that focus on creating value for HCPs could find new opportunities and improved access to those physicians, according to Accenture.
The cloud technology firm announced it will acquire Avalere in a move aimed at growing its relationships with pharma.
Click here to learn about the Agency Issue.
- When it comes to professional ads, print makes its comeback
- Amgen takes issue with yet-to-be published multiple-myeloma drug report
- How Watson for Oncology is advancing cancer care
- Creative partners should push pharma clients to tell better stories
- Retaining talent: How pharma can compete with Google